Recurrent disruption of long-range regulatory interactions at the 5q14.3 locus.
a. Genome-wide distribution of BCA breakpoints in the cohort across each 1-Mb bin. P-values correspond to observed vs. expected cluster sizes after 100,000 Monte Carlo randomizations. Corrected P-values are reported. One cluster, localized to 5q14.3, achieved genome-wide significance (threshold demarcated by red line); b. Hi-C profile and contact domains at the 5q14.3 locus derived from human LCLs. Overlapping Hi-C data suggests that the topology of the MEF2C-contact domain is altered in subjects carrying BCAs. Brain-expressed enhancers located in the region, loops involving MEF2C (yellow circles) and CTCF binding sites (green: forward, red: reverse) are indicated. Multiple pathogenic mechanisms converge on a similar syndrome: multi-genic deletions that encompass MEF2C along with one or both TAD boundaries (n=68), MEF2C-intragenic deletions (n=12) or LoF mutations, deletions that do not encompass MEF2C but overlap one TAD boundary (n=13), and BCA breakpoints distal to MEF2C (breakpoints from seven subjects reported in this study and three previously reported subjects),,.; c. Proposed model of the chromatin folding in the region defining a regulatory unit for MEF2C; d. Significantly decreased expression of MEF2C was observed in subjects harboring BCAs distal to MEF2C compared to controls. MEF2C-expression was measured by qRT-PCR, normalized against three endogenous genes and compared to the average MEF2C-expression from 16 age-matched controls (two-sided Wilcoxon rank-sum test: DGAP131, DGAP191, DGAP222: P=0.0085, DGAP218: P=0.0160). Individual expression values, median, first and third quartiles are indicated.